• Skip to primary navigation
  • Skip to main content
AMRA MedicalAMRA Medical

AMRA Medical

Precision for Decision

  • Career
  • Support
  • Contact Us
  • Solutions
    • Clinical Services
    • Research Services
  • Get Set Up
    • Get Set Up
    • Get a Quote
  • Science
    • What We Do
    • How We Do It
    • Why It Matters
    • Our Core Areas
    • Technology
  • News & Events
    • News
    • Events
  • Resources
    • Webinars
    • Publications
    • Whitepapers
    • Media
  • About Us
    • About AMRA
    • Our Team
    • Partners & Investors
  • Career
  • Support
  • Contact Us

AMRA Medical’s AASLD Presentations – A Body Composition Research Quartet

November 3, 2021
  • Facebook
  • Twitter
  • LinkedIn
  • Mail

LINKÖPING, Sweden; November 3, 2021—AMRA’s recent research using magnetic resonance imaging (MRI)-based body composition analysis on individuals with liver disease will be presented at The Liver Meeting, scheduled for November 12-15, 2021. Specifically, four abstracts have been accepted for poster presentation, which will be presented by an AMRA team member or research collaborator.

The Liver Meeting, hosted by the American Association for the Study of Liver Diseases (AASLD), brings together clinicians, associates, and scientists from around the world to exchange information on the latest research, discuss new developments in liver treatment and transplantation, and network with leading experts in hepatology.

AMRA’s poster titles include:

Non-Invasive Muscle Biomarkers Predict All-Cause Mortality In NAFLD

Radiomics Based Coronary Heart Disease Signature In Liver Transplant Recipients With Nonalcoholic Fatty Liver Disease

Liver Transplant Recipients With Nonalcoholic Fatty Liver Disease Have Worse Muscle Composition Profile

Natural Rate Of Change In Body Composition On Waitlist And The First 200 Days After Liver Transplant – Results From A Pilot Study

AMRA researchers used MRI to assess muscle and fat volumes in individuals with NAFLD. They found that muscle biomarkers describing muscle composition (muscle volume and fat infiltration) were associated with all-cause mortality in individuals with NAFLD. They also found that liver transplant recipients with NAFLD have distinctively higher visceral adipose tissue and relatively lower liver fat content—which are the characteristics of a coronary heart disease (CHD) phenotype.

In a separate study, liver transplant recipients with NAFLD had a poor muscle composition profile, suggesting a potential relationship between liver transplant and NAFLD as a key driver of an adverse muscle phenotype. In the pilot study, the researchers observed significant increases in muscle and adipose tissue volumes after liver transplant, and this could be explored further to assess how these changes impact functional performance and outcomes.

By attending AMRA’s presentations, researchers and clinicians can learn about the strengthened evidence for muscle composition measurements as important biomarkers in early and late stages of liver disease. The research also provides the foundation to design future studies in liver transplant settings exploring how muscle composition is associated with functional performance and outcomes or using radiomics for disease risk stratification.

Conference attendees can view ePoster content in a virtual poster hall through The Digital Experience, where global programming will all be available through the TLMdX platform and accessible no matter the time of day or night until February 15, 2022.

Learn more about this research by attending The Liver Meeting or reaching out to AMRA’s team via info@amramedical.com.

All posts
  • Facebook
  • Twitter
  • LinkedIn
  • Mail
AMRA Medical
Follow us

About

AMRA offers clinical services and research services to support transformative care and vital decision-making, from clinical research to clinical care.

  • Data Privacy Policy
  • Cookie Policy

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Contact

  • info@amramedical.com
  • +46 (0) 13 16 26 00
  • Contact Our Support

Newsletter

© 2025 AMRA Medical AB
AMRA Medical
Manage Cookie Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
View preferences
{title} {title} {title}
AMRA Medical
Manage Cookie Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
View preferences
{title} {title} {title}